Caffeine, Nicotine, and Cannabis: The Three Substances Nobody Declares Before Ibogaine Therapy

There is a specific way that pre-treatment screening fails, and it has nothing to do with dishonesty.

A patient sits down with an intake form. It asks what medications they take. They think carefully, and they answer carefully. They list the antidepressant, the blood pressure tablet, the thing for sleep. They do not list the four cups of coffee, the vape they use hourly, or the CBD oil they take every night for anxiety, because the form asked about medications and none of those are medications.

The form got an honest answer to the wrong question.

We have written before about the four ways prescribed medications go undisclosed: patients think "it's prescribed, so it's fine," they name a drug by its indication rather than its class, they discount anything taken only as needed, and they fear being disqualified. Caffeine, nicotine, and cannabis represent a fifth and larger failure mode, and it is the simplest of all: the patient does not classify the substance as a drug.

All three interact with the systems that safe ibogaine therapy screening is specifically designed to protect. Here is how.

Cannabis and CBD: The CYP2D6 Problem, Again

Ibogaine is metabolised principally by the liver enzyme CYP2D6, which converts it to its long-lived metabolite noribogaine. How fast that conversion happens is the single largest driver of how much unmetabolised ibogaine circulates, and for how long. A slow clearer accumulates drug.

We have already covered how bupropion, a strong CYP2D6 inhibitor, can convert a genetically normal metaboliser into a functionally poor one, a phenomenon called phenoconversion, in our analysis of ADHD medication and the CYP2D6 problem. The lesson there was that genotyping alone is insufficient, because a genetic test tells you what enzyme a patient was born with, not what enzyme they currently have available after everything else they take has finished blocking it.

Cannabidiol belongs in that same conversation.

CBD has been shown in laboratory studies to inhibit multiple cytochrome P450 enzymes, including CYP3A4, CYP2C19, and CYP2D6. The clinical magnitude of CBD's CYP2D6 inhibition in real patients is still being characterised and should not be overstated, but the direction of effect is not in dispute, and the doses people take casually are not small. Unregulated CBD products are frequently sold at concentrations far above what a clinical study would use, and product labelling in most markets is unreliable.

The screening problem is that almost nobody reports it. CBD is sold in supermarkets and wellness shops. It is marketed explicitly as not a drug. A patient who would never fail to mention a prescribed anxiolytic will take 50mg of CBD oil nightly for eighteen months and not think of it as relevant.

THC raises separate issues:

• Acute tachycardia and increased cardiac workload. THC reliably raises heart rate for a period after use, which complicates the interpretation of baseline cardiac readings taken on arrival.
• Cannabinoid hyperemesis syndrome. In some heavy long-term users, cannabis produces cycles of severe vomiting, classically relieved by hot showers. Ibogaine causes significant nausea and vomiting on its own. A patient who arrives with an unrecognised hyperemesis pattern presents a clinical picture that is extremely difficult to disentangle, and the shared consequence, sustained vomiting, drives fluid and electrolyte loss.
• Withdrawal. Cannabis withdrawal is real, with irritability, sleep disruption, appetite loss, and anxiety typically peaking in the first week. That timeline overlaps precisely with the treatment window, and every one of those symptoms is something a clinical team would otherwise attribute to the treatment itself.

Nicotine: The Enzyme Nobody Thinks About

Nicotine's own metabolism runs through CYP2A6, which is not ibogaine's pathway. If that were the end of it, nicotine would barely warrant a paragraph.

It is not the end of it, for two reasons.

First, smoking induces CYP1A2 — and quitting reverses it. The enzyme induction comes from polycyclic aromatic hydrocarbons in combustion smoke, not from nicotine itself. This means it applies to cigarettes and not to patches, gum, or most vapes. Smokers therefore run a substantially upregulated CYP1A2 system, and they clear CYP1A2 substrates faster than non-smokers do.

When a smoker stops abruptly, which is exactly what happens to many people entering a residential treatment setting, that induction unwinds over roughly a week. Blood levels of CYP1A2 substrates rise, sometimes considerably, on an unchanged dose. Clozapine and olanzapine are the best-documented examples, and the effect is large enough to be a recognised cause of toxicity in psychiatric practice. Duloxetine and theophylline are also affected.

Nobody prescribed anything new. Nobody took a larger dose. The patient simply stopped smoking, and their existing medication became a higher effective dose.

Second, nicotine is a sympathomimetic. It raises heart rate and blood pressure. Ibogaine, characteristically, does the opposite: it slows the heart, and bradycardia is one of the expected and closely monitored features of the experience. A patient using nicotine heavily has a competing influence on the exact variable the monitor is watching, which can partially mask a developing bradycardia in the same way stimulants do.

Nicotine withdrawal peaks around day three, bringing irritability, restlessness, poor concentration and disturbed sleep into the same window as the treatment. This is not dangerous. It is, however, a large and entirely avoidable source of diagnostic noise, and it is much better managed when the team knows about it in advance.

Caffeine: Small Drug, Real Consequences

Caffeine is the most consumed psychoactive substance on earth and the least likely to appear on any form.

It is a CYP1A2 substrate, which connects it directly to the smoking story above. Smokers metabolise caffeine roughly twice as fast as non-smokers. A patient who quits smoking on arrival but keeps drinking the same amount of coffee will experience a genuine increase in caffeine exposure at an unchanged intake, producing tremor, palpitations, anxiety and insomnia that will be read as withdrawal or as anticipatory anxiety.

Two further issues matter clinically:

Withdrawal. Caffeine withdrawal headache typically begins 12 to 24 hours after the last dose, peaks somewhere in the second day, and can persist for several days. It comes with fatigue, low mood, difficulty concentrating and nausea. Anyone who has read a first-hand account of what ibogaine therapy is like will recognise that list, because it overlaps almost entirely with what people expect from the treatment itself. A patient who tapers caffeine in the week before arrival removes that confound completely, at no cost.

Electrolytes. Caffeine has a modest diuretic effect, which on its own is unimportant. Combined with the vomiting and reduced oral intake that accompany treatment, it contributes to fluid loss, and fluid loss depletes potassium and magnesium. Low potassium and low magnesium prolong the QT interval. This is the same convergence point that almost every screening question eventually reaches, and it is set out in detail in our guide to ibogaine cardiac risks and QT prolongation.

Energy drinks deserve a specific mention, because a single large can may contain as much caffeine as three cups of coffee alongside other stimulant ingredients, and because people who consume them frequently describe themselves as not drinking much coffee.

What Good Screening Looks Like

The fix is the same one that works for prescription medications: reconciliation, not interrogation. You do not solve this by rewording a question. You solve it by changing the shape of the conversation.

A clinic conducting this properly will ask something closer to:

• Walk me through a normal day. What do you drink from the moment you wake up?
• Do you smoke, vape, or use any nicotine product? How many, and at what times?
• Do you use cannabis in any form, including CBD oil, gummies, tinctures, or topicals? What strength, how often, and for how long?
• Is there anything you take that you would not describe as a medication? Supplements, herbals, sleep aids, anything from a health food shop?
• Has anything about your intake changed in the last month?

That last question matters more than it looks. A patient who quit smoking three weeks ago to prepare for treatment is mid-way through an enzyme change and may be sitting on rising levels of an unchanged psychiatric prescription.

If you are preparing for treatment yourself, our ibogaine medication interaction checker and pre-screening assessment are useful places to organise your own list before a clinical conversation, and our full medication interaction reference covers the prescription side in depth.

Why the Clinic's Response Tells You Something

There is a diagnostic value in raising this yourself. Tell a prospective provider that you drink five coffees a day, vape constantly, and take CBD oil at night, and watch what happens.

A clinic doing this well will be interested. They will ask about strength and duration, they will want to know how long you have smoked, and they will give you a specific taper plan for the weeks before arrival, including caffeine.

A clinic that waves it off, tells you none of that matters, or seems mildly irritated that you asked, has just told you something important about how the rest of their screening is conducted. Our clinic selection checklist covers the other questions worth asking, and our overview of liver and kidney function screening explains why the organs that handle all of these substances need baseline assessment of their own.

The Short Version

Ibogaine screening is fundamentally about protecting cardiac conduction and preserving the CYP2D6 clearance pathway. Cannabis reaches the first through heart rate and vomiting-driven electrolyte loss, and the second through CBD's enzyme inhibition. Nicotine reaches both through CYP1A2 induction that reverses on quitting and through sympathomimetic effects on heart rate. Caffeine reaches them through CYP1A2 and through fluid and electrolyte loss.

None of the three will normally disqualify anyone. All three change what a responsible team does in the weeks before treatment. The only thing that reliably prevents them from being managed is that nobody wrote them down.

Bring the coffee, the vape, and the CBD bottle to the conversation. They belong on the list.

---

Medical disclaimer. Ibogaine Treatment Guide is an independent educational resource. We are not a treatment provider, we are not affiliated with any clinic, and nothing here is medical advice. Ibogaine carries documented cardiac risk and has been associated with fatalities, including in supervised settings. Never stop or adjust a prescribed medication without direct guidance from a qualified prescriber, and discuss any substance use, including caffeine, nicotine, and cannabis, honestly with a medical professional. If you are in crisis in the United States, call or text 988 for the Suicide and Crisis Lifeline.